Limitations, agreements, and source contact

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission · Source last updated 2021-06-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

restrictive Agreement

false

limitations And Caveats

description

The study was terminated early due to futility as determined by Amgen's Carfilzomib NASCR program in addition to low enrollment.

point Of Contact

email

vanrheefrits@uams.edu

organization

University of Arkansas for Medical Sciences

phone

501-526-2873

title

Frits Van Rhee, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice